PURE
PURE Bioscience, Inc.0.0500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.59MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
10-K
FY2025 results
PURE Bioscience posted FY2025 net product sales of $2.2 million, up 12% year-over-year, fueled by broader adoption in food processing via end-user and distributor channels, though one customer still drove 18% of revenue. This uptick narrowed the net loss to $2.4 million from $3.4 million in FY2024, with gross margins steady at 59% amid a shift to higher-margin bulk volumes. Sales momentum built through the year, but quarterly breakdowns remain undisclosed in the 10-K, limiting visibility into Q4 acceleration or sequential trends. Liquidity tightened to $409,000 in cash against $4.8 million in convertible notes, mostly to a director, underscoring ongoing funding needs. No annual guidance surfaced for FY2026. Auditors flag substantial doubt on going-concern viability.
8-K
PURE's sales up, loss down
PURE Bioscience reported fiscal 2025 results on October 29, 2025, with net product sales rising 12% to $2.2 million from $2.0 million in 2024, driven by expanded distribution. The net loss narrowed to $2.4 million from $3.4 million, thanks to cuts in personnel and facility costs, while cash burn eased to $2.0 million. Rebranding and new partnerships with Hydrite and Bonsai bolster dairy and beverage market penetration. Yet risks loom in product adoption and funding needs.
IPO
Website
Employees
Sector
Industry
CLX
Clorox Company (The)
99.82-1.90
DQWS
Dswiss Inc
0.04+0.00
HNST
The Honest Company, Inc.
2.86+0.05
PCT
PureCycle Technologies, Inc.
7.84-0.17
PG
Procter & Gamble Company (The)
145.21+0.08
PHH
Park Ha Biological Technology C
0.39-0.00
PLSE
Pulse Biosciences, Inc
14.23+0.10
PTNM
Pitanium Limited
10.39+0.00
PUBC
Purebase Corporation
0.04-0.01
UL
Unilever PLC
64.33-0.71